Evidence map›Paper›PMID 35568481›Full record

ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2022

How to Harness the Power of Social Media for Quality Drug Information in Infectious Diseases: Perspectives on Behalf of the Society of Infectious Diseases Pharmacists.

Kelli A Cole, Anna Y Zhou, Travis Jones, W Justin Moore, Elisabeth L Chandler, Veronica B Zafonte, Taylor Morrisette, Timothy P Gauthier, Jamie Kisgen, Amanda Barner and 3 more

Abstract read
In one paragraph

Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Kelli A ColeMedical Science Liaison, OH/MI/W. PA, ViiV Healthcare, Research Triangle Park, North Carolina, USA.
Anna Y ZhouDepartment of Pharmacy, Loma Linda University Health, Loma Linda, California, USA.
Travis JonesDivision of Infectious Diseases, Duke University Medical Center, Durham, North Carolina, USA.
W Justin MooreDepartment of Pharmacy, Northwestern Medicine, Chicago, Illinois, USA.
Elisabeth L ChandlerDepartment of Pharmacy, Lee Health, Fort Myers, Florida, USA.
Veronica B ZafonteDepartment of Pharmacy, Jamaica Hospital Medical Center, Richmond Hill, New York, USA.
Taylor MorrisetteDepartment of Clinical Pharmacy and Outcomes Sciences, Medical University of South Carolina College of Pharmacy, Charleston, South Carolina, USA.ORCID 0000-0002-1094-043X
Timothy P GauthierClinical Pharmacy Enterprise, Baptist Health South Florida, Miami, Florida, USA.
Jamie KisgenDepartment of Pharmacy, Sarasota Memorial Health Care System, Sarasota, Florida, USA.
Amanda BarnerDepartment of Pharmacy, Cambridge Health Alliance, Cambridge, Massachusetts, USA.
Melissa D JohnsonDivision of Infectious Diseases & International Health, Duke University Medical Center, Durham, North Carolina, USA.
R Dawn TagareDepartment of Pharmacy, University of Utah Health, Salt Lake City, Utah, USA.
Julie Ann JustoDepartment of Clinical Pharmacy and Outcomes Sciences, University of South Carolina College of Pharmacy, Columbia, South Carolina, USA.ORCID 0000-0002-4161-9577

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Clinicians, researchers, and the public frequently turn to digital channels and social media for up-to-the-minute information on novel therapeutics and vaccines. The value of credible infectious diseases drug information is more apparent in the setting of the coronavirus disease 2019 (COVID-19) pandemic. This viewpoint by the Society of Infectious Diseases Pharmacists (SIDP) provides guidance on utilizing social media platforms to optimize infectious diseases pharmacotherapy. It includes tips for all levels of users but primarily serves a guide for the infectious diseases clinician who has not yet joined social media. It compares various social media platforms and suggests which to begin with based on user needs, recommends efficient curation of social media content, and outlines a stepwise approach (shown below) to increasing engagement over time. This summary will hopefully spur further quality content and engagement regarding drug information from the infectious diseases social media network.

Indexed as

Communicable DiseasesCOVID-19Social MediaHumansPandemicsPharmacistsanti-infective agentscommunicable diseasescommunicationdrug informationsocial media

Identifiers

PMID35568481
PMCPMC9384058

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.